PA
SCLN

Profund Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Profund Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,294
Closed -$113K – 1487
2017
Q2 		$113K Buy
+10,294
New +$103K 0.01% 1393
2016
Q3 		– Sell
-10,830
Closed -$141K – 1509
2016
Q2 		$141K Buy
+10,830
New +$142K 0.01% 1399

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Profund Advisors's SCLN Position: Q3 2017 in Review

Profund Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 10,294 shares — an estimated $113K sold.

Profund Advisors first reported a position in SCLN in Q2 2016 and held it in 2 quarters. The position peaked at $141K in Q2 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Profund Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Profund Advisors sold 10,294 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $113K.
  • Profund Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 2 quarters.
  • Profund Advisors's Sciclone Pharmaceuticals Inc position peaked at $141K in Q2 2016.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Profund Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.